Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's ...

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

An Israeli study found patients taking Ozempic or similar weight-loss shots were twice as likely to suffer from a serious degenerative eye disease compared to those not on the medication.

Several studies have revealed a connection between GLP-1s and eye-related issues ... the active ingredient in Ozempic and Wegovy. Researchers paired patients with similar characteristics, such ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision ...